45.42
-1.07%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Hangzhou Alltest Biotech Co
Its shares trade on Shanghai under the ticker 688606.SS. It has been listed since 25 March 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥911.3m and net income of CN¥218.3m. At that date it held total assets of CN¥4.24bn and shareholders' equity of CN¥3.95bn.
Hangzhou Alltest Biotech Co., Ltd. engages in the development, production and sales of in vitro diagnostic reagents. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2021-03-25. The Company’s main products are rapid diagnostic reagents, including drug and drug abuse testing, infectious disease testing, women’s health testing, tumor testing, and heart marker testing. The firm's products are widely used in clinical testing, on-site testing and personal health management, especially in some new drug testing, new coronavirus testing, tropical infectious disease testing, respiratory all-in-one inspection, pediatric diarrhea all-in-one inspection and all-in-one joint inspection of fecal occult blood and other fields. The firm's main business is mainly distributed in overseas regions.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 25 Mar 2021
- Employees
- 1,244
- Website
- alltests.com.cn ↗
Leadership
Pay as last reported
- Mr. Fei GaoChairman of the Board, General Manager, since 2017CN¥829,400
- Ms. Yanping FuFinance Director, Secretary of the BoardCN¥506,800
- Mr. Weike LuDeputy General Manager, Director, since 2017CN¥668,700
- Mr. Huafang ZhaoDirector
- Mr. Zhanwang ZhengIndependent Director
- Mr. Yali ZhouIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Rapid diagnostic reagents for drug and drug abuse testing are widely used in clinical settings.
- Infectious disease testing products are key in new coronavirus and tropical disease management.
- Overseas regions are the main market for Alltest Biotech's main business.
Weaknesses
- The company's headquarters city Hangzhou is not a major global hub for biotech innovation.
- Alltest Biotech's IPO date March 25, 2021, is not a significant market event.
- The company's employee count 1,244 is below industry average for large biotech firms.
Opportunities
- New drug testing applications expand Alltest Biotech's market reach in health care.
- Tropical infectious disease testing opportunities in emerging markets are growing.
- Respiratory all-in-one inspection products are in high demand globally.
Threats
- Overseas market dependence poses risks from geopolitical tensions.
- Competition in the health care sector is intensifying globally.
- Rapid diagnostic reagents face regulatory challenges in new markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.